


The Hospital Medicines List (HML)

# Section H

## for Hospital Pharmaceuticals

Update effective 1 March 2016

Cumulative for December 2015,  
January, February and March 2016



## **Contents**

Summary of decisions effective 1 March 2016 .....	3
Section H changes to Part II .....	5
Index .....	46

## Summary of decisions

EFFECTIVE 1 MARCH 2016

- Aspirin tab EC 300 mg – presentation to be delisted 1 March 2016
- Budesonide with eformoterol powder for inhalation 100 mcg with eformoterol fumarate 6 mcg, 200 mcg with eformoterol fumarate 6 mcg and 400 mcg with eformoterol fumarate 12 mcg, and aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg and 200 mcg with eformoterol fumarate 6 mcg – restriction removed
- Cholecalciferol (Vit.D3) cap 1.25 mg (50,000 iu) – new listing
- Cholecalciferol (Cal-d-Forte) tab 1.25 mg (50,000 iu) – to be delisted 1 March 2016
- Diatrizoate sodium (Ioscan) oral liq 370 mg per ml, 10 ml sachet – new Pharmacode
- Doxorubicin hydrochloride inj 50 mg vial – new listing
- Doxorubicin hydrochloride (Doxorubicin Ebewe) inj 2 mg per ml, 25 ml vial – addition of note
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended restriction
- Filgrastim (Zarzio) inj 300 mcg in 0.5 ml and 400 mcg in 0.5 ml prefilled syringes – amended presentation description and price decrease
- Fluticasone furoate with vilanterol (Breo Ellipta) powder for inhalation 100 mcg with vilanterol 25 mcg – new listing
- Fluticasone with salmeterol aerosol inhaler 50 mcg with salmeterol 25 mcg and 125 mcg with salmeterol 25 mcg (Seretide), and powder for inhalation 100 mcg with salmeterol 50 mcg and 250 mcg with salmeterol 50 mcg (Seretide Accuhaler) – price decrease
- Gefitinib (Iressa) tab 250 mg – amended restriction
- Glycopyrronium (Seeebri Breezhaler) powder for inhalation 50 mcg per dose – restriction removed and amended note
- Glycopyrronium with indacaterol (Ultibro Breezhaler) powder for inhalation 50 mcg with indacaterol 110 mcg – new listing
- Haemophilus influenzae type B vaccine (Act-HIB) inj 10 mcg vial with diluent syringe – amended restriction
- Ketamine (Ketamine-Clarix) inj 100 mg per ml, 2 ml ampoule – amended presentation description, new listing and addition of HSS
- Metoprolol succinate (Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg and 95 mg, 90 tab pack size – new listing and addition of HSS
- Metoprolol succinate (Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg and 95 mg, 30 tab pack size – to be delisted 1 June 2016

## Summary of decisions – effective 1 March 2016 (continued)

- Moroctocog alfa [Recombinant factor VIII] (Xyntha) inj prefilled syringe 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu – amended restriction
  - Nonacog gamma [Recombinant factor IX] (RIXUBIS) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu and 3,000 iu vials – new listing with restriction
  - Octocog alfa [Recombinant factor VIII] (Advate) inj 250 iu, 500 iu, 1,000 iu, 1,500 iu, 2,000 iu, and 3,000 iu vials – amended chemical name and amended restriction
  - Octocog alfa [Recombinant factor VIII] (Kogenate FS) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu, and 3,000 iu vials – amended chemical name and amended restriction
  - Orphenadrine hydrochloride tab 50 mg – presentation to be delisted 1 March 2016
  - Pine tar with trolamine laurilsulfate and fluorescein (Pinetarsol) soln 2.3% with trolamine laurilsulfate and fluorescein sodium – amended chemical name and presentation description
  - Pneumococcal (PPV23) polysaccharide vaccine (Pneumovax 23) inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – amended restriction
  - Salmeterol aerosol inhaler 25 mcg per dose (Serevent) and powder for inhalation 50 mcg per dose (Serevent Accuhaler) – price decrease
  - Spacer device (Volumatic) 800 ml – price decrease
  - Tiotropium bromide (Spiriva Respimat) soln for inhalation 2.5 mcg per dose – new listing
  - Tiotropium bromide (Spiriva) powder for inhalation 18 mcg per dose – amended note and restriction moved from Long-Acting Muscarinic Agents group to tiotropium bromide chemical
  - Tiotropium bromide with olodaterol (Spiolto Respimat) soln for inhalation 2.5 mcg per dose with olodaterol 2.5 mcg – new listing
  - Umeclidinium (Incruse Ellipta) powder for inhalation 62.5 mcg per dose – new listing
  - Umeclidinium with vilanterol (Anoro Ellipta) powder for inhalation 62.5 mcg with vilanterol 25 mcg – new listing
  - Valaciclovir (Vaclovir) tab 500 mg and 1,000 mg – restriction removed
  - Varenicline (Champix) tab 0.5 mg x 11 and 1 mg x 14, and tab 1 mg – amended restriction
  - Varicella vaccine [chicken pox vaccine] (Varilrix) inj 2,000 PFU vial with diluent – amended restriction
-

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 March 2016

### ALIMENTARY TRACT AND METABOLISM

26	CHOLECALCIFEROL			
	Cap 1.25 mg (50,000 iu) .....	3.85	12	Vit.D3
	Note – Cal-d-Forte tab 1.25 mg (50,000 iu) to be delisted from 1 March 2016.			

### BLOOD AND BLOOD FORMING ORGANS

29	MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII]			
	→ Inj 250 iu prefilled syringe .....	210.00	1	Xyntha
	→ Inj 500 iu prefilled syringe .....	420.00	1	Xyntha
	→ Inj 1,000 iu prefilled syringe .....	840.00	1	Xyntha
	→ Inj 2,000 iu prefilled syringe .....	1,680.00	1	Xyntha
	→ Inj 3,000 iu prefilled syringe .....	2,520.00	1	Xyntha

Restricted

**Preferred Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

29	NONACOG GAMMA [RECOMBINANT FACTOR IX] (new listing)			
	→ Inj 250 iu vial.....	287.50	1	RIXUBIS
	→ Inj 500 iu vial.....	575.00	1	RIXUBIS
	→ Inj 1,000 iu vial.....	1,150.00	1	RIXUBIS
	→ Inj 2,000 iu vial.....	2,300.00	1	RIXUBIS
	→ Inj 3,000 iu vial.....	3,450.00	1	RIXUBIS

Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

30	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE)			
	→ Inj 250 iu vial .....	287.50	1	Advate
	→ Inj 500 iu vial .....	575.00	1	Advate
	→ Inj 1,000 iu vial .....	1,150.00	1	Advate
	→ Inj 1,500 iu vial .....	1,725.00	1	Advate
	→ Inj 2,000 iu vial .....	2,300.00	1	Advate
	→ Inj 3,000 iu vial .....	3,450.00	1	Advate

Restricted

**Rare Clinical Circumstances Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:**

**The Co-ordinator, Haemophilia Treatments Panel  
PHARMAC, PO Box 10 254  
Wellington**

**Phone: 0800 023 588 Option 2  
Facsimile: (04) 974 4881  
Email: [haemophilia@pharmac.govt.nz](mailto:haemophilia@pharmac.govt.nz)**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 March 2016 (continued)

30	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] ( <b>KOGENATE FS</b> )		
	→ Inj 250 iu vial .....	237.50	1 Kogenate FS
	→ Inj 500 iu vial .....	475.00	1 Kogenate FS
	→ Inj 1,000 iu vial .....	950.00	1 Kogenate FS
	→ Inj 2,000 iu vial .....	1,900.00	1 Kogenate FS
	→ Inj 3,000 iu vial .....	2,850.00	1 Kogenate FS

Restricted

**Second Brand of recombinant factor VIII from 1 March 2016 until 28 February 2019. When used in the treatment of haemophilia, access to funded treatment by application to the Haemophilia Treatments Panel.**

**Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:**

**The Co-ordinator, Haemophilia Treatments Panel**

**Phone: 0800 023 588 Option 2**

**PHARMAC, PO Box 10 254**

**Facsimile: (04) 974 4881**

**Wellington**

**Email: [haemophilia@pharmac.govt.nz](mailto:haemophilia@pharmac.govt.nz)**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

33	FILGRASTIM (amended presentation description and ↓ price)		
	→ Inj 300 mcg in 0.5 ml <b>prefilled</b> syringe .....	270.00	5 Zarzio
	→ Inj 480 mcg in 0.5 ml <b>prefilled</b> syringe .....	432.00	5 Zarzio

## CARDIOVASCULAR SYSTEM

40	METOPROLOL SUCCINATE (new pack size and addition of HSS)		
	Tab long-acting 23.75 mg – <b>1% DV Jun-16 to 2018</b> .....	2.39	90 <b>Metoprolol - AFT CR</b>
	Tab long-acting 47.5 mg – <b>1% DV Jun-16 to 2018</b> .....	3.48	90 <b>Metoprolol - AFT CR</b>
	Tab long-acting 95 mg – <b>1% DV Jun-16 to 2018</b> .....	5.73	90 <b>Metoprolol - AFT CR</b>
	Note – Metoprolol - AFT CR tab long-acting 23.75 mg, 47.5 mg and 95 mg, 30 tab packs, to be delisted from 1 June 2016.		

## DERMATOLOGICALS

53	<del>GOAL</del> <b>PINE TAR WITH TROLAMINE LAURILSULFATE TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN</b> (amended chemical and presentation names)		
	Soln 2.3% with <del>soln 2.3% with</del> <b>trolamine laurilsulfate triethanolamine lauryl sulfate</b> and fluorescein sodium .....	3.36	500 ml Pinetarsol
		5.82	1,000 ml Pinetarsol

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 March 2016 (continued)

### INFECTIONS

89	VALACICLOVIR			
	Tab 500 mg – <b>1% DV Mar-16 to 2018</b> .....	6.42	30	<b>Vaclovir</b>
	Tab 1,000 mg – <b>1% DV Mar-16 to 2018</b> .....	12.75	30	<b>Vaclovir</b>
	<i>Restricted-</i>			
	<i>Initiation – Immunocompetent patients-</i>			
	<i>Any of the following:-</i>			
	1 – Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily; or			
	2 – Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment; or			
	3 – Patient has undergone organ transplantation.			
	<i>Initiation – Immunocompromised patients-</i>			
	<i>Limited to 7 days treatment</i>			
	<i>Both:-</i>			
	1 – Patient is immunocompromised; and			
	2 – Patient has herpes zoster.			

### NERVOUS SYSTEM

102	ORPHENADRINE HYDROCHLORIDE			
	Tab 50 mg			
	Note – orphenadrine hydrochloride tab 50 mg to be delisted from 1 March 2016.			
103	KETAMINE (amended presentation description, new listing and addition of HSS)			
	Inj 100 mg per ml, 2 ml <b>ampoule vial</b>			
	– <b>1% DV May-16 to 2018</b> .....	47.05	5	<b>Ketamine-Claris</b>
106	ASPIRIN			
	Tab EC 300 mg			
	Note – Aspirin tab EC 300 mg to be delisted from 1 March 2016.			
127	VARENICLINE (amended restriction)			
	→ Tab 0.5 mg x 11 and 1 mg x 14 .....	60.48	25	Champix
	→ Tab 1 mg .....	67.74	28	Champix
		135.48	56	Champix
	<i>Restricted</i>			
	<i>All of the following:</i>			
	1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and			
	2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and			
	3 Either:			
	3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or			
	3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and			
	4 The patient has not used funded varenicline in the last 12 months; and			

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 March 2016 (continued)**

*continued...*

- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than **12 weeks'** ~~3 months'~~ funded varenicline in a 12 month period.

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

128	DOXORUBICIN HYDROCHLORIDE (new listing) Inj 50 mg vial			
128	DOXORUBICIN HYDROCHLORIDE (addition of note) Inj 2 mg per ml, 25 ml vial – <b>1% DV Feb-16 to 2018</b> .....	23.00	1	<b>Doxorubicin Ebewe</b>

Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.

134	ERLOTINIB → Tab 100 mg – <b>1% DV Jun-15 to 2018</b> .....	1,000.00	30	<b>Tarceva</b>
	→ Tab 150 mg – <b>1% DV Jun-15 to 2018</b> .....	1,500.00	30	<b>Tarceva</b>

Restricted  
Initiation  
*Re-assessment required after 4 months*  
Either:  
 † All of the following:  
 †-1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and  
 †-2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and  
 †-3 Any of the following:  
 †-3.1 Patient is treatment naive; or  
 †-3.2 Both:  
 †-3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and  
 †-3.2.2 Patient has not received prior treatment with gefitinib; or  
 †-3.3 Both:  
 †-3.3.1 The patient has discontinued gefitinib within **12 6** weeks of starting treatment due to intolerance; and  
 †-3.3.2 The cancer did not progress while on gefitinib; and  
 †-4 Erlotinib is to be given for a maximum of 3 months. ~~or~~  
 †-5 ~~The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.~~  
 Continuation  
*Re-assessment required after 6 months*  
 Both:  
 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and  
 2 Erlotinib is to be given for a maximum of 3 months.

→ Restriction  
(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 March 2016 (continued)**

134	<p>GEFITINIB</p> <p>→ Tab 250 mg ..... 1,700.00</p> <p>30</p> <p>Iressa</p> <p>Restricted</p> <p>Initiation</p> <p><i>Re-assessment required after 4 months</i></p> <p>All of the following:</p> <p>1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and</p> <p>2 Either:</p> <p>2.1 Patient is treatment naive; or</p> <p>2.2 Both:</p> <p>2.2.1 The patient has discontinued erlotinib within <b>12 6</b> weeks of starting treatment due to intolerance; and</p> <p>2.2.2 The cancer did not progress whilst on erlotinib; and</p> <p>3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and</p> <p>4 Gefitinib is to be given for a maximum of 3 months.</p> <p>Continuation</p> <p><i>Re-assessment required after 6 months</i></p> <p>Both:</p> <p>1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and</p> <p>2 Gefitinib is to be given for a maximum of 3 months.</p>		
-----	---	--	--

**RESPIRATORY SYSTEM AND ALLERGIES**

173	<p>GLYCOPYRRONIUM (restriction removed and note amended)</p> <p>Note: <b>inhaled</b> glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium <b>or umeclidinium</b>.</p> <p>Restricted</p> <p>Initiation</p> <p>All of the following:</p> <p>1 <del>To be used for the long term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and</del></p> <p>2 <del>In addition to standard treatment, the patient has trialed a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and</del></p> <p>3 <del>Either the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:</del></p> <p><del>3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or</del></p> <p><del>3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and</del></p> <p>4 <del>Actual FEV1 as a % of predicted, must be below 60%.</del></p> <p>5 <del>Either:</del></p> <p><del>5.1 Patient is not a smoker (for reporting purposes only); or</del></p> <p><del>5.2 Patient is a smoker and has been offered smoking cessation counselling; and</del></p> <p>6 <del>The patient has been offered annual influenza immunization.</del></p> <p>Powder for inhalation 50 mcg per dose ..... 61.00</p> <p>30 dose</p> <p>Seebri Breezhaler</p>		
-----	---	--	--

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 March 2016 (continued)**

173	<p><b>TIOTROPIUM BROMIDE (new listing)</b>            Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.</p> <p><b>Restricted</b>  <b>Initiation</b>            All of the following:</p> <ol style="list-style-type: none"> <li>1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and</li> <li>2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and</li> <li>3 Either the patient’s breathlessness according to the Medical Research Council (UK) dyspnoea scale is:               <ol style="list-style-type: none"> <li>3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or</li> <li>3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and</li> </ol> </li> <li>4 Actual FEV<sub>1</sub> as a % of predicted, must be below 60%.</li> <li>5 Either:               <ol style="list-style-type: none"> <li>5.1 Patient is not a smoker (for reporting purposes only); or</li> <li>5.2 Patient is a smoker and has been offered smoking cessation counselling; and</li> </ol> </li> <li>6 The patient has been offered annual influenza immunization.</li> </ol> <p>➔ Soln for inhalation 2.5 mcg per dose..... 70.00    60 dose    Spiriva Respimat</p>		
173	<p><b>TIOTROPIUM BROMIDE (amended note and restriction moved from Long-Acting Muscarinic Agents group to tiotropium bromide chemical)</b>            Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised <b>inhaled</b> glycopyrronium <b>or umeclidinium</b>.</p> <p><b>Restricted</b>  <b>Initiation</b>            All of the following:</p> <ol style="list-style-type: none"> <li>1 <b>To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and</b></li> <li>2 <b>In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and</b></li> <li>3 <b>Either the patient’s breathlessness according to the Medical Research Council (UK) dyspnoea scale is:</b> <ol style="list-style-type: none"> <li>3.1 <b>Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or</b></li> <li>3.2 <b>Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and</b></li> </ol> </li> <li>4 <b>Actual FEV<sub>1</sub> as a % of predicted, must be below 60%.</b></li> <li>5 <b>Either:</b> <ol style="list-style-type: none"> <li>5.1 <b>Patient is not a smoker (for reporting purposes only); or</b></li> <li>5.2 <b>Patient is a smoker and has been offered smoking cessation counselling; and</b></li> </ol> </li> <li>6 <b>The patient has been offered annual influenza immunization.</b></li> </ol> <p>➔ Powder for inhalation 18 mcg per dose..... 70.00    30 dose    Spiriva</p>		
173	<p><b>UMECLIDINIUM (new listing)</b>            Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.</p> <p>Powder for inhalation 62.5 mcg per dose..... 61.50    30 dose    Incruse Ellipta</p>		

➔ Restriction  
 (Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 March 2016 (continued)**

174 LONG-ACTING MUSCARINIC ANTAGONISTS WITH LONG-ACTING BETA-ADRENOCEPTOR AGONISTS

(new therapeutic subgroup with restriction and note)

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

Restricted

Initiation

*Re-assessment required after 2 years*

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

*Re-assessment required after 2 years*

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

174 GLYCOPYRRONIUM WITH INDACATEROL (new listing)

Restricted

Initiation

*Re-assessment required after 2 years*

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

*Re-assessment required after 2 years*

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

→ Powder for inhalation 50 mcg with indacaterol 110 mcg .....81.00 30 dose Ultibro Breezhaler

174 TIOTROPIUM BROMIDE WITH OLODATEROL (new listing)

Restricted

Initiation

*Re-assessment required after 2 years*

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

*Re-assessment required after 2 years*

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

→ Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg .....81.00 60 dose Spiolto Respimat

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 March 2016 (continued)**

174	<b>UMECLIDINIUM WITH VILANTEROL (new listing)</b> Restricted Initiation <i>Re-assessment required after 2 years</i> Both: 1 Patient has been stabilised on a long acting muscarinic antagonist; and 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product. Continuation <i>Re-assessment required after 2 years</i> Both: 1 Patient is compliant with the medication; and 2 Patient has experienced improved COPD symptom control (prescriber determined). ➔ Powder for inhalation 62.5 mcg with vilanterol 25 mcg ..... 77.00      30 dose      Anoro Ellipta		
175	<b>SALMETEROL (↓ price)</b> Aerosol inhaler 25 mcg per dose ..... 25.00      120 dose      Serevent Powder for inhalation 50 mcg per dose ..... 25.00      60 dose      Serevent Accuhaler		
176	<b>BUDESONIDE WITH EFORMOTEROL</b> Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg Restricted Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or 2 All of the following: 2.1 Patient is over the age of 12; and 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.		
176	<b>FLUTICASONE FUROATE WITH VILANTEROL (new listing)</b> Powder for inhalation 100 mcg with vilanterol 25 mcg ..... 44.08      30 dose      Breo Ellipta		
176	<b>FLUTICASONE WITH SALMETEROL (↓ price)</b> Aerosol inhaler 50 mcg with salmeterol 25 mcg ..... 33.74      120 dose      Seretide Powder for inhalation 100 mcg with salmeterol 50 mcg ..... 33.74      60 dose      Seretide Accuhaler Aerosol inhaler 125 mcg with salmeterol 25 mcg ..... 44.08      120 dose      Seretide Powder for inhalation 250 mcg with salmeterol 50 mcg ..... 44.08      60 dose      Seretide Accuhaler		

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 March 2016 (continued)

### VACCINES

210	HAEMOPHILUS INFLUENZAE TYPE B VACCINE → Inj 10 mcg vial with diluent syringe – 1% DV Jul-14 to 2017..... 0.00	1	<b>Act-HIB</b>
	Restricted One dose for patients meeting any of the following:		
	1 For primary vaccination in children; or		
	2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; <b>functional asplenic</b> ; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or		
	3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.		
211	PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE → Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 1% DV Jun-15 to 2017 ..... 0.00	1	<b>Pneumovax 23</b>
	Restricted Any of the following:		
	1 Up to three doses ( <b>as appropriate</b> ) for patients <b>with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy</b> ; pre- or post-splenectomy; <del>or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency</del> ; or		
	2 Up to two doses are funded for high risk children to the age of 18; or		
	3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.		
214	VARICELLA VACCINE [CHICKEN POX VACCINE] → Inj 2,000 PFU vial with diluent – 1% DV Jul-14 to 2017 ..... 0.00	1	<b>Varilrix</b>
	Restricted Therapy limited to 2 doses Any of the following:		
	1 For non-immune patients:		
	1.1 with chronic liver disease who may in future be candidates for transplantation; or		
	1.2 with deteriorating renal function before transplantation; or		
	1.3 prior to solid organ transplant; or		
	1.4 prior to any elective immunosuppression*; <b>or</b> <b>1.5 for post exposure prophylaxis who are immune competent inpatients.</b>		
	2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist.		
	3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist.		
	4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.		
	5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.		
	6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.		
	7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella		
	* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 March 2016 (continued)

### VARIOUS

187	DIATRIZOATE SODIUM Oral liq 370 mg per ml, 10 ml sachet .....	156.12	50	Ioscan
	Note – this is the addition of a new Pharmacode 2495686, which is not registered.			

### PART III - OPTIONAL PHARMACEUTICALS

216	SPACER DEVICE (↓ price) 800 ml .....	6.50	1	Volumatic
-----	---	------	---	-----------

## Effective 1 February 2016

### ALIMENTARY TRACT AND METABOLISM

15	GLYCOPYRRONIUM BROMIDE (↓ price and extension of HSS) Inj 200 mcg per ml, 1 ml ampoule – <b>1% DV Oct-13 to 2019 2016</b> .....	17.14	10	Max Health
----	--	-------	----	------------

### HORMONE PREPARATIONS

60	DEXAMETHASONE PHOSPHATE (brand name change, ↓ price and extension of HSS) Inj 4 mg per ml, 1 ml ampoule – <b>1% DV Apr-14 to 2019 2016</b> .....	14.19	10	Max Health Dexamethasone- hameln
	Inj 4 mg per ml, 2 ml ampoule – <b>1% DV Apr-14 to 2019 2016</b> .....	12.59	5	Max Health Dexamethasone- hameln
62	TETRACOSACTIDE [TETRACOSACTRIN] (pack size change) Inj 250 mcg per ml, 1 ml ampoule .....	17.71	1	Synacthen
	Note – pack size change from 10 inj to 1 inj pack. The 10 injection pack size to be delisted from 1 April 2016.			

### INFECTIONS

72	AMOXICILLIN WITH CLAVULANIC ACID (↑ price) Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml.....	3.83	100 ml	Augmentin
	Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml.....	4.97	100 ml	Augmentin
73	MOXIFLOXACIN (presentation change) ➔ Inj 1.6 mg per ml, 250 ml bottle.....	70.00	1	Avelox IV 400
	Note – this is a presentation change from a bag to bottle. Avelox IV 400 infusion bag will be delisted from 1 April 2016.			

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 February 2016 (continued)

### MUSCULOSKELETAL SYSTEM

92	NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE (↓ price and extension of HSS) Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – <b>1% DV Nov-13 to 2019 2016</b> .....	20.90	10	<b>Max Health</b>
----	---	-------	----	-------------------

### NERVOUS SYSTEM

103	DESFLURANE (↑ price) Soln for inhalation 100%, 240 ml bottle.....	1,414.50	6	Suprane
103	ISOFLURANE (↑ price) Soln for inhalation 100%, 250 ml bottle.....	1,173.00	6	Aerrane
104	SEVOFLURANE (↑ price) Soln for inhalation 100%, 250 ml bottle.....	1,365.00	6	Baxter
114	LEVETIRACETAM Tab 250 mg .....	24.03	60	Everet
	Tab 500 mg .....	28.71	60	Everet
	Tab 750 mg .....	45.23	60	Everet
	Tab 1,000 mg .....	59.12	60	Everet
	Note – Levetiracetam-Rex tab 250 mg, 500 mg and 750 mg to be delisted from 1 August 2016.			
116	RIZATRIPTAN (additional pack size) Tab orodispersible 10 mg – <b>1% DV Sep-14 to 2017</b> .....	3.24	12	<b>Rizamelt</b>
122	DIMETHYL FUMARATE → Cap 120 mg .....	520.00	14	Tecfidera
	→ Cap 240 mg .....	2,000.00	56	Tecfidera
	Restricted Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).			
122	TERIFLUNOMIDE → Tab 14 mg .....	1,582.62	28	Aubagio
	Restricted Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).			

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

131	ETOPOSIDE Inj 20 mg per ml, 5 ml vial – <b>1% DV Apr-16 to 2018</b> .....	7.90	1	<b>Rex Medical</b>
	Note – Hospira etoposide inj 20 mg per ml, 5 ml vial to be delisted from 1 April 2016.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 January 2016

### ALIMENTARY TRACT AND METABOLISM

14	MESALAZINE (new listing) Tab 800 mg .....	85.55	90	Asacol
----	--	-------	----	--------

### CARDIOVASCULAR SYSTEM

44	EZETIMIBE (Pharmacode change) → Tab 10 mg – <b>1% DV Aug-15 to 2017</b> .....	3.35	30	<b>Ezemibe</b>
	Note – Pharmacode change from a blister pack to bottle. The blister will be delisted from 1 July 2016.			

### DERMATOLOGICALS

50	ISOTRETINOIN (HSS suspended) Cap 10 mg – <b>1% DV Nov-15 to 31/12/15 2018</b> .....	12.47	100	Isotane 10
	Cap 20 mg – <b>1% DV Nov-15 to 31/12/15 2018</b> .....	19.27	100	Isotane 20
50	ISOTRETINOIN (new listing) Cap 10 mg .....	14.96	120	Oratane
	Cap 20 mg .....	23.12	120	Oratane
51	AQUEOUS CREAM Crm 500 g – <b>1% DV Mar-16 to 2018</b> .....	1.99	500 g	<b>AFT SLS-free</b>
	<b>Note: DV limit applies to the pack sizes of greater than 100 g.</b>			
	Note – AFT aqueous cream 500 g to be delisted from 1 March 2016.			

### INFECTIONS

72	AMOXICILLIN (new listing) Grans for oral liq 125 mg per 5 ml .....	2.00	100 ml	Ospamox
	Grans for oral liq 250 mg per 5 ml .....	2.00	100 ml	Ospamox
73	CIPROFLOXACIN → Inj 2 mg per ml, 100 ml bag – <b>1% DV Mar-16 to 2018</b> .....	30.58	10	<b>Cipflox</b>
	Note – Aspen Ciprofloxacin inj 2 mg per ml, 100 ml bag to be delisted from 1 March 2016.			
79	RIFAMPICIN (discontinuation) → Tab 600 mg – <b>1% DV Nov-14 to 2017</b> .....	108.70	30	<b>Rifadin</b>
	Note – Rifadin tab 600 mg to be delisted from 1 March 2016.			
89	VALACICLOVIR → Tab 500 mg – <b>1% DV Mar-16 to 2018</b> .....	6.42	30	<b>Vaclovir</b>
	→ Tab 1,000 mg – <b>1% DV Mar-16 to 2018</b> .....	12.75	30	<b>Vaclovir</b>
	Note – Valtrex tab 500 mg to be delisted from 1 March 2016.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 January 2016 (continued)**

**NERVOUS SYSTEM**

116	SUMATRIPTAN (HSS suspended) Inj 12 mg per ml, 0.5 ml cartridge – 1% DV Sep-13 to 31/12/15 2016 .....	13.80	2	Arrow-Sumatriptan
120	ZIPRASIDONE (restriction removed) Cap 20 mg – 1% DV Jan-16 to 2018..... Cap 40 mg – 1% DV Jan-16 to 2018..... Cap 60 mg – 1% DV Jan-16 to 2018..... Cap 80 mg – 1% DV Jan-16 to 2018.....	14.56 24.75 33.87 39.74	60 60 60 60	<b>Zusdone</b> <b>Zusdone</b> <b>Zusdone</b> <b>Zusdone</b>
	Restricted 1—Patient is suffering from schizophrenia or related psychoses; and 2—Either: 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.			

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

128	BLEOMYCIN SULPHATE (amended presentation description) Inj 15,000 iu (10 mg) vial – 1% DV Oct-15 to 2018 .....	150.48	1	<b>DBL Bleomycin Sulfate</b>
133	OXALIPLATIN Inj 5 mg per ml, 10 ml vial – 1% DV Mar-16 to 2018 .....	13.32	1	<b>Oxallicord</b>
	Inj 5 mg per ml, 20 ml vial – 1% DV Mar-16 to 2018 .....	16.00	1	<b>Oxallicord</b>
	Note – Oxaliplatin Actavis 50 inj 50 mg vial and Oxaliplatin Actavis 100 inj 100 mg vial to be delisted from 1 March 2016.			
147	ADALIMUMAB (new listing) → Inj 10 mg per 0.2 ml prefilled syringe .....	1,599.96	2	Humira
147	ADALIMUMAB (↓ price) → Inj 20 mg per 0.4 ml syringe..... → Inj 40 mg per 0.8 ml pen .....	1,599.96 1,599.96	2 2	Humira HumiraPen
	→ Inj 40 mg per 0.8 ml syringe.....	1,599.96	2	Humira
154	INFLIXIMAB (amended restriction – affected criteria only) → Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020 .....	806.00	1	<b>Remicade</b>
	Initiation – fistulising Crohn’s disease Gastroenterologist <b>Re-assessment required after 4 months Therapy limited to 4 doses</b> All of the following: 1 Patient has confirmed Crohn’s disease; and 2 Either: 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or 2.2 Patient has one or more rectovaginal fistula(e).			
	Initiation – plaque psoriasis, prior TNF use			

*continued...*

Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	-------------------------------------

## Changes to Section H Part II – effective 1 January 2016 (continued)

*continued...*

Dermatologist

**Re-assessment required after** Therapy limited to 3 doses

**Either:**

**1** Both:

1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or

1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or

**2** All of the following:

**2.1** Either:

2.1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or

2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

**2.2** Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated):

phototherapy, methotrexate, ciclosporin, or acitretin; and

**2.3** A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

**2.4** The most recent PASI assessment is no more than 1 month old at the time of initiation.

**Note:** “Inadequate response” is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initiation — plaque psoriasis, treatment-naïve

Dermatologist

Therapy limited to 3 doses

All of the following:

**1** Either:

1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or

1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

**2** Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, thotrexate, ciclosporin, or acitretin; and

**3** A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

**4** The most recent PASI assessment is no more than 1 month old at the time of initiation.

*continued...*

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 January 2016 (continued)

continued...

Note: “Inadequate response” is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

### RESPIRATORY SYSTEM AND ALLERGIES

172	ICATIBANT (new listing) → Inj 10 mg per ml, 3 ml prefilled syringe .....	2,668.00	1	Firazyr
	Restricted Initiation Clinical immunologist or relevant specialist <i>Re-assessment required after 12 months</i> Both: 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and 2 The patient has undergone product training and has agreed upon an action plan for self-administration. Continuation Re-assessment required after 12 months The treatment remains appropriate and the patient is benefiting from treatment.			

### SENSORY ORGANS

178	CHLORAMPHENICOL (↑ price) Eye oint 1% .....	3.19	4 g	Chlorsig
180	MIXED SALT SOLUTION FOR EYE IRRIGATION (Pharmacode change) Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle – <b>1% DV Jan-16 to 2018</b> .....	10.50	500 ml	<b>Balanced Salt Solution</b>
	Note – Pharmacode change from 500615 to 286850. Pharmacode 500615 to be delisted from 1 January 2016.			

### EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

193	GLYCERIN WITH SODIUM SACCHARIN (↓ price) Suspension .....	32.50	473 ml	Ora-Sweet SF
193	GLYCERIN WITH SUCROSE (↓ price) Suspension .....	32.50	473 ml	Ora-Sweet
193	METHYLCELLULOSE (↓ price) Suspension .....	32.50	473 ml	Ora-Plus

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 January 2016 (continued)

193	METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN (↓ price) Suspension .....	32.50	473 ml	Ora-Blend SF
193	METHYLCELLULOSE WITH GLYCERIN AND SUCROSE (↓ price) Suspension .....	32.50	473 ml	Ora-Blend

### SPECIAL FOODS

203	EXTENSIVELY HYDROLYSED FORMULA → Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can			<i>e.g. Aptamil Gold+ Pepti Junior</i>
-----	---	--	--	--

#### Restricted

Initiation – new patients

Any of the following:

1 Both:

1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and

1.2 Either:

1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or

1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or

2 Severe malabsorption; or

3 Short bowel syndrome; or

4 Intractable diarrhoea; or

5 Biliary atresia; or

6 Cholestatic liver diseases causing malabsorption; or

7 Cystic fibrosis; or

8 Proven fat malabsorption; or

9 Severe intestinal motility disorders causing significant malabsorption; or

10 Intestinal failure; or

**11 For step down from Amino Acid Formula.**

Note: A reasonable trial is defined as a 2-4 week trial, **or signs of an immediate IgE mediated allergic reaction.**

Initiation – step down from amino acid formula

Both:

1 The infant is currently receiving funded amino acid formula; and

2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.

Continuation

Both:

1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and

2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2015

### ALIMENTARY TRACT AND METABOLISM

24	NYSTATIN (new listing) Oral liquid 100,000 u per ml – <b>1% DV Feb-16 to 2017</b> ..... 2.55      24 ml <b>m-Nystatin</b> Note – Nilstat oral liquid 100,000 u per ml to be delisted from 1 February 2016
24	<del>               NYSTATIN (<del>price and delisting</del>) – Decision recinded                Oral liquid 100,000 u per ml ..... 2.55      24 ml      Nilstat             </del>

### BLOOD AND BLOOD FORMING ORGANS

31	RIVAROXABAN (amended restriction) <b>→</b> Tab 10 mg ..... 153.00      15      Xarelto Restricted Either: 1— Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or 2— Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.  <b>Initiation — total hip replacement</b> <b>Therapy limited to 5 weeks</b> <b>For the prophylaxis of venous thromboembolism.</b>  <b>Initiation — total knee replacement</b> <b>Therapy limited to 2 weeks</b> <b>For the prophylaxis of venous thromboembolism.</b>
----	--

### INFECTIONS

73	DEMECLOXYCLINE HYDROCHLORIDE (new listing) Tab 150 mg
73	MOXIFLOXACIN (amended restriction) <b>→</b> Tab 400 mg ..... 52.00      5      Avelox <b>→</b> Inj 1.6 mg per ml, 250 ml bottle ..... 70.00      1      Avelox IV 400 Restricted Initiation — Mycobacterium infection Infectious disease specialist, clinical microbiologist or respiratory specialist Either: 1 <b>Both:</b> <b>1.1</b> Active tuberculosis; <del>and</del> <del>with</del> <b>1.2</b> any of the following: <b>1.2.1</b> <del>1-1</del> Documented resistance to one or more first-line medications; or <b>1.2.2</b> <del>1-2</del> Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or <b>1.2.3</b> <del>1-3</del> Impaired visual acuity (considered to preclude ethambutol use); or <b>1.2.4</b> <del>1-4</del> Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or <b>1.2.5</b> <del>1-5</del> Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.

Initiation — Pneumonia

Infectious disease specialist or clinical microbiologist

**Either:**

- 1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
- 2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

Initiation — Penetrating eye injury

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

Initiation — Mycoplasma genitalium

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

85 ADEFOVIR DIPIVOXIL (amended restriction)

→ Tab 10 mg ..... 670.00      30      Hepsera

Restricted

Gastroenterologist or infectious disease specialist

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:
  - 2+ Patient has raised serum ALT (> 1 × ULN); and
  - 32 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
  - 43 Detection of M204I or M204V mutation; and
- 54 Either:
  - 54.1 Both:
    - 54.1.1 Patient is cirrhotic; and
    - 54.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
  - 54.2 Both:
    - 54.2.1 Patient is not cirrhotic; and
    - 54.2.2 Adefovir dipivoxil to be used as monotherapy.

89 VALACICLOVIR (amended restriction)

→ Tab 500 mg ..... 102.72      30      Valtrex

Restricted

**Initiation – Immunocompetent patients**

Any of the following:

- 1 Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily; or
- 2 Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment; or
- 3 Patient has undergone organ transplantation.

**Initiation – Immunocompromised patients**

*Limited to 7 days treatment*

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has herpes zoster.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

90	PEGYLATED INTERFERON ALFA-2A (amended restriction)		
	→ Inj 135 mcg prefilled syringe		
	→ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)		
	→ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)		
	→ Inj 180 mcg prefilled syringe .....	900.00	4 Pegasys
	→ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112).....	1,159.84	1 Pegasys RBV Combination Pack
	→ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168).....	1,290.00	1 Pegasys RBV Combination Pack

**Restricted**

Initiation – Chronic hepatitis C – genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

**Therapy limited to 48 weeks**

**Both:**

† Any of the following:

- †:1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- †:2 Patient has chronic hepatitis C and is co-infected with HIV; or
- †:3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

~~2 – Maximum of 48 weeks therapy.~~

**Notes:**

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – (Chronic hepatitis C – genotype 1 infection)

Gastroenterologist, infectious disease specialist or general physician

**Therapy limited to 48 weeks**

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; ~~and~~
- ~~5 – Maximum of 48 weeks therapy.~~

Initiation (Chronic Hepatitis C – genotype 1 infection treatment more than 4 years prior)

Gastroenterologist, infectious disease specialist or general physician

**Therapy limited to 48 weeks**

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; ~~and~~
- ~~5 – Maximum of 48 weeks therapy.~~

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

Initiation – Chronic hepatitis C – genotype 2 or 3 infection without co-infection with HIV

**Therapy limited to 6 months**

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 ~~Maximum of 6 months therapy.~~

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

**Therapy limited to 48 weeks**

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log<sub>10</sub> IU/ml; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 ~~Maximum of 48 weeks therapy.~~

Notes:

Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

**MUSCULOSKELETAL SYSTEM**

92	ALENDRONATE SODIUM (amended restriction) ➔ Tab 40 mg .....	133.00	30	Fosamax
----	---	--------	----	---------

Restricted

**Initiation – Paget's disease**

Both:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
  - 2.5 Preparation for orthopaedic surgery.

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

92	<p>ALENDRONATE SODIUM (amended restriction – affected criterion only)</p> <p>→ Tab 70 mg ..... 12.90</p> <p>Restricted</p> <p>Initiation — Osteoporosis</p> <p>Any of the following:</p> <ol style="list-style-type: none"> <li>1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≥ -2.5) (see Note); or</li> <li>2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or</li> <li>3 History of two significant osteoporotic fractures demonstrated radiologically; or</li> <li>4 Documented T-Score ≤ -3.0 (see Note); or</li> <li>5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or</li> <li>6 Patient has had a Special Authority approval for zoledronic acid (<b>underlying cause</b> – osteoporosis) or raloxifene.</li> </ol>	4	Fosamax
93	<p>ALENDRONATE SODIUM WITH CHOLECALCIFEROL (amended restriction – affected criterion only)</p> <p>→ Tab 70 mg with cholecalciferol 5,600 iu ..... 12.90</p> <p>Restricted</p> <p>Initiation — Osteoporosis</p> <p>Any of the following:</p> <ol style="list-style-type: none"> <li>1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≥ -2.5) (see Note); or</li> <li>2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or</li> <li>3 History of two significant osteoporotic fractures demonstrated radiologically; or</li> <li>4 Documented T-Score ≤ -3.0 (see Note); or</li> <li>5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or</li> <li>6 Patient has had a Special Authority approval for zoledronic acid (<b>underlying cause</b> – osteoporosis) or raloxifene.</li> </ol>	4	Fosamax Plus
97	<p>TERIPARATIDE (amended restriction)</p> <p>→ Inj 250 mcg per ml, 2.4 ml cartridge..... 490.00</p> <p>Restricted</p> <p><i>Limited to 18 months' treatment</i></p> <p>All of the following:</p> <ol style="list-style-type: none"> <li>1 The patient has severe, established osteoporosis; and</li> <li>2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and</li> <li>3 The patient has had two or more fractures due to minimal trauma; and</li> <li>4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).</li> </ol> <p>Notes:</p> <ol style="list-style-type: none"> <li>1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable</li> <li>2 Antiresorptive agents and their adequate doses for the purposes of this <b>restriction</b> Special Authority</li> </ol>	1	Forteo

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

100 MELOXICAM (amended restriction)

→ Tab 7.5 mg

Restricted

Either:

1 Haemophilic arthropathy, with both of the following:

**1 All of the following:**

**1.1 Haemophilic arthropathy; and**

**1.2** 1-1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and

**1.3** 1-2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or

- 2 For preoperative and/or postoperative use for a total of up to 8 days' use.

**NERVOUS SYSTEM**

103 DESFLURANE (Pharmacode change)

Soln for inhalation 100%, 240 ml bottle..... 1,230.00 6 Suprane

Note – Suprane bottle presentation changed, so Pharmacode change from 2331551 to 2490293.

Pharmacode 2331551 to be delisted from 1 February 2016.

109 OXYCODONE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule – **1% DV Feb-16 to 2018** ..... 8.57 5 **OxyNorm**

Inj 10 mg per ml, 2 ml ampoule – **1% DV Feb-16 to 2018** ..... 16.89 5 **OxyNorm**

Note – Oxycodone Orion inj 10 mg per ml, 1 ml and 2 ml ampoules to be delisted from 1 February 2016.

112 GABAPENTIN (amended restriction – affected criteria only)

→ Cap 100 mg..... 7.16 100 Arrow-Gabapentin

Neurontin

Nupentin

→ Cap 300 mg..... 11.00 100 Arrow-Gabapentin

Neurontin

Nupentin

→ Cap 400 mg..... 13.75 100 Arrow-Gabapentin

Neurontin

Nupentin

Restricted

1 For preoperative and/or postoperative use for up to a total of 8 days' use; or

2 For the pain management of burns patients with monthly review.

**Initiation — preoperative and/or postoperative use**

**Therapy limited to 8 days**

**Initiation — pain management of burns patients**

**Re-assessment required after 1 month**

*continued...*

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**  
*continued...*

**Continuation – pain management of burns patients**

***Re-assessment required after 1 month***

**The treatment remains appropriate and the patient is benefiting from the treatment.**

115 VIGABATRIN (amended restriction)

→ Tab 500 mg

Restricted

**Initiation**

***Re-assessment required after 15 months***

Both:

1 Either:

1.1 Patient has infantile spasms; or

1.2 Both:

1.2.1 Patient has epilepsy; and

1.2.2 Either:

1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes:

"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Continuation**

**Both:**

**1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and**

**2 Either:**

**2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or**

**2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.**

**Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.**

**Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.**

116 PIZOTIFEN (new listing)

Tab 500 mcg – **1% DV Sep-15 to 2018**.....23.21 100 **Sandomigran**

Note – this is the listing of the bottle presentation. The blister pack also remains listed.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

124	DEXAMFETAMINE SULFATE (amended restriction) → Tab 5 mg – <b>1% DV Dec-15 to 2018</b> .....	17.00	100	<b>PSM</b>
	Restricted <b>Initiation</b> – ADHD Paediatrician or psychiatrist Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria <b>Initiation</b> – Narcolepsy Neurologist or respiratory specialist <b>Re-assessment required after 24 months</b> Patient suffers from narcolepsy <b>Continuation</b> – Narcolepsy Neurologist or respiratory specialist <b>Re-assessment required after 24 months</b> <b>The treatment remains appropriate and the patient is benefiting from the treatment.</b>			
125	METHYLPHENIDATE HYDROCHLORIDE (amended restriction – affected criteria only) → Tab extended-release 18 mg .....	58.96	30	Concerta
	→ Tab extended-release 27 mg .....	65.44	30	Concerta
	→ Tab extended-release 36 mg .....	71.93	30	Concerta
	→ Tab extended-release 54 mg .....	86.24	30	Concerta
	→ Tab immediate-release 5 mg .....	3.20	30	Rubifen
	→ Tab immediate-release 10 mg .....	3.00	30	Ritalin
				Rubifen
	→ Tab immediate-release 20 mg .....	7.85	30	Rubifen
	→ Tab sustained-release 20 mg .....	10.95	30	Rubifen SR
		50.00	100	Ritalin SR
	→ Cap modified-release 10 mg .....	15.60	30	Ritalin LA
	→ Cap modified-release 20 mg .....	20.40	30	Ritalin LA
	→ Cap modified-release 30 mg .....	25.52	30	Ritalin LA
	→ Cap modified-release 40 mg .....	30.60	30	Ritalin LA
	Restricted <b>Initiation</b> — Narcolepsy (immediate-release and sustained-release formulations) Neurologist or respiratory specialist <b>Re-assessment required after 24 months</b> Patient suffers from narcolepsy. <b>Continuation</b> – Narcolepsy (immediate-release and sustained-release formulations) Neurologist or respiratory specialist <b>Re-assessment required after 24 months</b> <b>The treatment remains appropriate and the patient is benefiting from the treatment.</b>			
125	MODAFINIL (amended restriction) → Tab 100 mg Restricted <b>Initiation</b> Neurologist or respiratory specialist <b>Re-assessment required after 24 months</b> All of the following: 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and 2 Either:			

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
- 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
  - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialed and discontinued because of intolerable side effects; or
  - 3.2 Methylphenidate and dexamphetamine are contraindicated.

**Continuation – Narcolepsy**

**Neurologist or respiratory specialist**

**Re-assessment required after 24 months**

**The treatment remains appropriate and the patient is benefiting from the treatment.**

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

128	DOXORUBICIN HYDROCHLORIDE (new listing)			
	Inj 2 mg per ml, 25 ml vial – <b>1% DV Feb-16 to 2018</b> .....	11.50	1	<b>Doxorubicin Ebewe</b>
	Inj 2 mg per ml, 50 ml vial – <b>1% DV Feb-16 to 2018</b> .....	23.00	1	<b>Doxorubicin Ebewe</b>
	Inj 2 mg per ml, 100 ml vial – <b>1% DV Feb-16 to 2018</b> .....	46.00	1	<b>Doxorubicin Ebewe</b>
	Note – Arrow-Doxorubicin inj 2 mg per ml, 25 ml and 100 ml vials to be delisted from 1 February 2016.			

128	DOXORUBICIN HYDROCHLORIDE (delisting)			
	Inj 50 mg vial			
	Note – Doxorubicin hydrochloride inj 50 mg vial to be delisted from 1 February 2016.			

129	AZACITIDINE (amended restriction)			
	→ Inj 100 mg vial .....	605.00	1	Vidaza

Restricted

Initiation

Haematologist

*Re-assessment required after 12 months*

All of the following:

1 Any of the following:

- 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
- 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
- 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and

2 The patient has performance status (WHO/ECOG) grade 0-2; and

3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and

4 The patient has an estimated life expectancy of at least 3 months.

*Notes: Indication marked with a \* is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score > 80), and in patients who have had at least a partial resection of the tumour.*

Continuation

Haematologist

*Re-assessment required after 12 months*

Both:

1 No evidence of disease progression, and

2 The treatment remains appropriate and patient is benefiting from treatment.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

130	BORTEZOMIB (amended restriction)		
	→ Inj 1 mg vial.....	540.70	1 Velcade
	→ Inj 3.5 mg vial.....	1,892.50	1 Velcade
	Restricted		
	Initiation – treatment naive multiple myeloma/amyloidosis		
	<b>Re-assessment required after 15 months</b>		
	Both:		
	1 Either:		
	1.1 The patient has treatment-naive symptomatic multiple myeloma; or		
	1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and		
	2 Maximum of 9 treatment cycles.		
	Note: Indications marked with * are Unapproved Indications.		
	Initiation – relapsed/refractory multiple myeloma/amyloidosis		
	<b>Re-assessment required after 8 months</b>		
	All of the following:		
	1 Either:		
	1.1 The patient has relapsed or refractory multiple myeloma; or		
	1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and		
	2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and		
	3 The patient has not had prior publicly funded treatment with bortezomib; and		
	4 Maximum of 4 treatment cycles.		
	Note: Indications marked with * are Unapproved Indications.		
	Continuation – relapsed/refractory multiple myeloma/amyloidosis		
	<b>Re-assessment required after 8 months</b>		
	Both:		
	1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and		
	2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).		
	Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:		
	1 A known therapeutic chemotherapy regimen and supportive treatments; or		
	2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.		
	Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.		
132	TEMOZOLOMIDE (amended restriction)		
	→ Cap 5 mg – 1% DV Sep-13 to 2016.....	8.00	5 <b>Temaccord</b>
	→ Cap 20 mg – 1% DV Sep-13 to 2016.....	36.00	5 <b>Temaccord</b>
	→ Cap 100 mg – 1% DV Sep-13 to 2016.....	175.00	5 <b>Temaccord</b>
	→ Cap 250 mg – 1% DV Sep-13 to 2016.....	410.00	5 <b>Temaccord</b>
	Restricted		
	All of the following:		
	1 Either:		
	1.1 Patient has newly diagnosed glioblastoma multiforme; or		
	1.2 Patient has newly diagnosed anaplastic astrocytoma*; and		
	2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and		
	3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m <sup>2</sup> .		
	Notes: Indication marked with a * is an Unapproved Indication. <b>Temozolomide is not funded for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.</b> Studies of temozolomide		

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**  
*continued...*

show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

133	THALIDOMIDE (amended restriction)			
	→ Cap 50 mg.....	378.00	28	Thalomid
	→ Cap 100 mg.....	756.00	28	Thalomid

Restricted

Initiation

**Re-assessment required after 12 months**

Any of the following:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis\*; or
- 3 The patient has erythema nodosum leprosum.

Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with \* is an Unapproved Indication

134	ERLOTINIB (amended restriction)			
	→ Tab 100 mg – 1% DV Jun-15 to 2018 .....	1,000.00	30	<b>Tarceva</b>
	→ Tab 150 mg – 1% DV Jun-15 to 2018 .....	1,500.00	30	<b>Tarceva</b>

Restricted

Initiation

**Re-assessment required after 4-3 months**

**Therapy limited to 3 months**

Either:

- 1 All of the following:
  - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
  - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
  - 1.3 Any of the following:
    - 1.3.1 Patient is treatment naive; or
    - 1.3.2 Both:
      - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
      - 1.3.2.2 Patient has not received prior treatment with gefitinib; or
    - 1.3.3 Both:
      - 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
      - 1.3.3.2 The cancer did not progress while on gefitinib; ~~and~~ **or**
  - 1.4 Erlotinib is to be given for a maximum of 3 months, or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Continuation

**Re-assessment required after 6 months**

**Therapy limited to 3 months**

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

134	GEFITINIB (amended restriction)			
	→ Tab 250 mg .....	1,700.00	30	Iressa
	Restricted Initiation			
	<i>Re-assessment required after 4-3 months</i>			
	<b>Therapy limited to 3 months</b>			
	All of the following:			
	1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and			
	2 Either:			
	2.1 Patient is treatment naive; or			
	2.2 Both:			
	2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and			
	2.2.2 The cancer did not progress whilst on erlotinib; and			
	3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.			
	Continuation			
	<i>Re-assessment required after 6 months</i>			
	<b>Therapy limited to 3 months</b>			
	Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.			
134	IMATINIB MESILATE (amended restriction)			
	Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.			
	→ Tab 100 mg .....	2,400.00	60	Glivec
	Restricted Initiation			
	<i>Re-assessment required after 12 months</i>			
	Both:			
	1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and			
	2 Maximum dose of 400 mg/day.			
	Continuation			
	<i>Re-assessment required after 12 months</i>			
	Adequate clinical response to treatment with imatinib (prescriber determined).			
	<b>Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.</b>			
137	SUNITINIB (amended restriction – affected criteria only)			
	→ Cap 12.5 mg.....	2,315.38	28	Sutent
	→ Cap 25 mg.....	4,630.77	28	Sutent
	→ Cap 50 mg.....	9,261.54	28	Sutent
	Restricted Initiation – RCC			
	<i>Re-assessment required after 3 months</i>			
	1 The patient has metastatic renal cell carcinoma; and			
	2 Any of the following:			
	2.1 The patient is treatment naive; or			
	2.2 The patient has only received prior cytokine treatment; or			

continued...



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
- 2.4 Both:
  - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
  - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
  - 5.2 Haemoglobin level < lower limit of normal; or
  - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
  - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
  - 5.5 Karnofsky performance score of  $\leq$  70; or
  - 5.6  $\geq$  2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

**Notes: RCC – Sunitinib treatment should be stopped if disease progresses.**

**Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.**

Continuation – GIST

*Re-assessment required after 6 months*

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
  - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
  - 1.2 The patient has had a partial response (a decrease in size of  $\geq$  10% or decrease in tumour density in Hounsfield Units (HU) of  $\geq$  15% on CT and no new lesions and no obvious progression of non-measurable disease); or
  - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

**Notes: RCC – Sunitinib treatment should be stopped if disease progresses.**

**Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.**

GIST – It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of  $\geq$  10% and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

141	ETANERCEPT (amended restriction – affected criteria only)			
	→ Inj 25 mg vial .....	799.96	4	Enbrel
	→ Inj 50 mg autoinjector .....	1,599.96	4	Enbrel
	→ Inj 50 mg syringe .....	1,599.96	4	Enbrel

Restricted

Initiation – adult-onset Still's disease

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the **Section H HML** rules; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
  - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

147 ADALIMUMAB (amended restriction – affected criteria only)

➔ Inj 20 mg per 0.4 ml syringe .....	1,799.92	2	Humira
➔ Inj 40 mg per 0.8 ml pen.....	1,799.92	2	HumiraPen
➔ Inj 40 mg per 0.8 ml syringe .....	1,799.92	2	Humira

Restricted  
Continuation – rheumatoid arthritis  
Rheumatologist  
*Re-assessment required after 6 months*

- All of the following:
- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2 Either:
    - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
    - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
  - 3 Adalimumab to be administered at doses no greater than **40 mg every 14 days 50 mg every 7 days**.

Initiation – adult-onset Still's disease  
Rheumatologist  
*Re-assessment required after 6 months*

- Either:
- 1 Both:
    - 1.1 Either:
      - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
      - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the **Section H HML** rules; and
    - 1.2 Either:
      - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
  - 2 All of the following:
    - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
    - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
    - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

➔ Restriction  
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

154	<p>INFLIXIMAB (amended restriction – affected criteria only)  <b>→ Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020</b> .....</p>	806.00	1	<b>Remicade</b>
	<p>Restricted            Initiation – rheumatoid arthritis            Rheumatologist  <i>Re-assessment required after 4 3-4 months</i>            All of the following:</p> <ol style="list-style-type: none"> <li>1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and</li> <li>2 Either:               <ol style="list-style-type: none"> <li>2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or</li> <li>2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and</li> </ol> </li> <li>3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.</li> </ol> <p>Initiation – psoriatic arthritis            Rheumatologist  <i>Re-assessment required after 4 3-4 months</i>            Both:</p> <ol style="list-style-type: none"> <li>1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and</li> <li>2 Either:               <ol style="list-style-type: none"> <li>2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or</li> <li>2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.</li> </ol> </li> </ol> <p>Continuation – Crohn's disease (adults)            Gastroenterologist  <i>Re-assessment required after 6 months</i>  <b>Both All of the following:</b></p> <ol style="list-style-type: none"> <li>1 <b>Any One</b> of the following:               <ol style="list-style-type: none"> <li>1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or</li> <li>1.2 CDAI score is 150 or less; or</li> <li>1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and</li> </ol> </li> <li>2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and</li> <li>3 <del>Patient must be reassessed for continuation after further 6 months.</del></li> </ol> <p>Continuation – Crohn's disease (children)            Gastroenterologist  <i>Re-assessment required after 6 months</i>  <b>Both All of the following:</b></p> <ol style="list-style-type: none"> <li>1 <b>Any One</b> of the following:               <ol style="list-style-type: none"> <li>1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or</li> <li>1.2 PCDAI score is 15 or less; or</li> </ol> </li> </ol>			

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2015 (continued)

continued...

- 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- ~~3 Patient must be reassessed for continuation after further 6 months.~~

Initiation – fistulising Crohn's disease  
Gastroenterologist

### **Therapy limited to 4 doses**

**Both All of the following:**

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); and
- ~~3 Patient must be reassessed for continuation after 4 months of therapy~~

Continuation – fistulising Crohn's disease  
Gastroenterologist

### **Re-assessment required after 6 months**

**Both All of the following:**

- 1 Either:
  - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
  - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- ~~3 Patient must be reassessed for continuation after further 6 months.~~

Initiation – acute severe fulminant ulcerative colitis  
Gastroenterologist

### **Re-assessment required after 6 weeks**

**Both All of the following:**

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
- ~~3 Patient must be reassessed for continuation after 6 weeks of therapy.~~

Continuation – severe fulminant ulcerative colitis  
Gastroenterologist

### **Re-assessment required after 6 months**

**Both All of the following:**

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- ~~3 Patient must be reassessed for continuation after further 6 months.~~

Initiation – severe ulcerative colitis  
Gastroenterologist

continued...

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

**Re-assessment required after 3 months**

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
  - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is  $\geq 4$ ; or
  - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is  $\geq 65$ ; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 ~~— Patient must be reassessed for continuation after 3 months of therapy.~~

Continuation – severe ulcerative colitis  
Gastroenterologist

**Re-assessment required after 6 months**

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
  - 2.1 Patient is 18 years or older and the SCCAI score has reduced by  $\geq 2$  points from the SCCAI score when the patient was initiated on infliximab; or
  - 2.2 Patient is under 18 years and the PUCAI score has reduced by  $\geq 30$  points from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis, prior TNF use  
Dermatologist

**Therapy limited to 3 doses Re-assessment required after 3 doses**

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
  - 2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

160	RITUXIMAB (amended restriction – affected criteria only)		
	→ Inj 10 mg per ml, 10 ml vial.....	1,075.50	2
	→ Inj 10 mg per ml, 50 ml vial.....	2,688.30	1

Restricted

Initiation – rheumatoid arthritis – prior TNF inhibitor use  
Rheumatologist

**Re-assessment required after 4 months 2 doses**

All of the following:

- 1 Both:
  - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
    - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2015 (continued)

*continued...*

- 2 Either:
  - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis – TNF inhibitors contraindicated

Rheumatologist

*Re-assessment required after 4 months 2-doses*

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
  - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
  - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
  - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
  - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
  - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
  - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
  - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis – re-treatment in 'partial responders' to rituximab

Rheumatologist

*Re-assessment required after 4 months 2-doses*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis – re-treatment in ‘responders’ to rituximab  
Rheumatologist

*Re-assessment required after 4 months 2-doses*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

166 TOCILIZUMAB (amended restriction – affected criteria only)

→ Inj 20 mg per ml, 4 ml vial.....	220.00	1	Actemra
→ Inj 20 mg per ml, 10 ml vial.....	550.00	1	Actemra
→ Inj 20 mg per ml, 20 ml vial.....	1,100.00	1	Actemra

Restricted

Initiation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 All of the following:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
  - 1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the **Section H HME** rules; and
  - 1.4 Either:
    - 1.4.1 The patient has experienced intolerable side effects from rituximab; or
    - 1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
  - 2.2 Tocilizumab is to be used as monotherapy; and
  - 2.3 Either:
    - 2.3.1 Treatment with methotrexate is contraindicated; or

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 2.4 Either:
  - 2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
  - 2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 2.5 Either:
  - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
  - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.6 Either:
  - 2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation – adult-onset Still’s disease

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for **adalimumab and/or** etanercept for adult-onset Still’s disease (AOSD); and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
  - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**RESPIRATORY SYSTEM AND ALLERGIES**

174 SODIUM CHLORIDE (amended presentation)  
Aqueous nasal spray **isotonic 7.4 mg per ml**

175 MONTELUKAST (amended restriction – affected criterion only)

➔ Tab 4 mg.....	18.48	28	Singulair
➔ Tab 5 mg.....	18.48	28	Singulair
➔ Tab 10 mg.....	18.48	28	Singulair

Initiation – Pre-school wheeze

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) **in children under 5 years**; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

➔ Restriction  
(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

117	DORNASE ALFA (amended restriction) → Nebuliser soln 2.5 mg per 2.5 ml ampoule .....	250.00	6	Pulmozyme
	Restricted Any of the following:			
	1 Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or			
	2 Significant mucus production and meets the following criteria			
	3 Treatment for up to four weeks for patients meeting the following:			
	3.1 Patient is an in-patient; and			
	3.2 The mucus production cannot be cleared by first line chest techniques; or			
	4 Treatment for up to three days for patients diagnosed with empyema.			

**Initiation – cystic fibrosis**

The patient has cystic fibrosis and has been approved for funding by the Cystic Fibrosis Panel.

**Initiation – significant mucus production**

*Therapy limited to 4 weeks*

**Both:**

- 1 Patient is an inpatient; and
- 2 The mucus production cannot be cleared by first line techniques.

**Initiation – pleural empyema**

*Therapy limited to 3 days*

**Both:**

- 1 Patient is an inpatient; and
- 2 Patient diagnosed with pleural empyema.

**VARIOUS**

185	DESFERIOXAMINE MESILATE Inj 500 mg vial – <b>1% DV Feb-16 to 2018</b> .....	51.52	10	<b>Desferal</b>
	Note – Hospira desferrioxamine mesilate inj 500 mg vial to be delisted from 1 February 2016.			

**SPECIAL FOODS**

201	PEPTIDE-BASED ORAL FEED (new listing) → Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle .....	18.06	1,000 ml	Vital
201	PEPTIDE-BASED ORAL FEED (delisting) → Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet .....	4.40	79 g	Vital HN
	Note – Vital HN powder, 79 g sachet to be delisted from 1 February 2016.			
203	EXTENSIVELY HYDROLYSED FORMULA (amended example brand) → Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can .....			<b>Aptamil Gold+ Pepti Junior Gold Pepti Junior Karicare Aptamil</b>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2015 (continued)

### VACCINES

210	BACILLUS CALMETTE-GUERIN VACCINE (amended restriction) → Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent – <b>1% DV Oct-14 to 2017</b> .....	0.00	10	<b>BCG Vaccine</b>
	Restricted <b>All of the following:</b> For infants at increased risk of tuberculosis <b>defined as:</b> <del>Note: increased risk is defined as:</del> 1 Living in a house or family with a person with current or past history of TB; or 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.  Note: A list of countries with high rates of TB are available at <a href="http://www.health.govt.nz/tuberculosis">http://www.health.govt.nz/tuberculosis</a> (Search for Downloads) or <a href="http://www.bcgatlas.org/index.php">www.bcgatlas.org/index.php</a>			
210	HAEMOPHILUS INFLUENZAE TYPE B VACCINE (amended restriction) → Inj 10 mcg vial with diluent syringe – <b>1% DV Jul-14 to 2017</b> ....	0.00	1	<b>Act-HIB</b>
	Restricted <b>Therapy limited to 1 dose</b> <b>Any of the following:</b> <del>One dose for patients meeting any of the following:</del> 1 For primary vaccination in children; or 2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
212	HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] (amended restriction) → Inj 120 mcg in 0.5 ml syringe – <b>1% DV Jul-14 to 2017</b> .....	0.00	10	<b>Gardasil</b>
	Restricted <b>Therapy limited to 3 doses</b> <b>Any of the following:</b> <del>Maximum of three doses for patient meeting any of the following criteria:</del> 1 Females aged under 20 years old; or 2 Patients aged under 26 years old with confirmed HIV infection; or 3 For use in transplant (including stem cell) patients; or 4 An additional dose for patients under 26 years of age post chemotherapy.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

213	INFLUENZA VACCINE (amended restriction) → Inj 45 mcg in 0.5 ml syringe.....	90.00	10	Fluarix Influvac
-----	--	-------	----	---------------------

Restricted

**Initiation – People over 65**

**The patient is 65 years of age or over.**

**Initiation – cardiovascular disease**

Any of the following:

1 All people 65 years of age and over; or

2 People under 65 years of age who:

2.1 Have any of the following cardiovascular diseases:

2.1.1 Ischaemic heart disease; or

2.1.2 Congestive heart failure; or

2.1.3 Rheumatic heart disease; or

2.1.4 Congenital heart disease; or

2.1.5 Cerebro-vascular disease; ~~or~~

**Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.**

**Initiation – chronic respiratory disease**

**Either:**

2.2 Have any of the following chronic respiratory diseases:

2.2.1 Asthma, if on a regular preventative therapy; or

2.2.2 Other chronic respiratory disease with impaired lung function. ~~or~~

**Note: asthma not requiring regular preventative therapy is excluded from funding.**

**Initiation – other conditions**

**Either:**

**1 Any of the following:**

1.1 ~~2.3~~ Have diabetes; or

1.2 ~~2.4~~ Have chronic renal disease; or

1.3 ~~2.5~~ Have any cancer, excluding basal and squamous skin cancers if not invasive; or

2.6 Have any of the following other conditions:

1.4 ~~2.6.1~~ Autoimmune disease; or

1.5 ~~2.6.2~~ Immune suppression or immune deficiency; or

1.6 ~~2.6.3~~ HIV; or

1.7 ~~2.6.4~~ Transplant recipients; or

1.8 ~~2.6.5~~ Neuromuscular and CNS diseases/ disorders; or

1.9 ~~2.6.6~~ Haemoglobinopathies; or

1.10 ~~2.6.7~~ ~~Are children~~ **Is a child** on long term aspirin; or

1.11 ~~2.6.8~~ ~~Have~~ **Has** a cochlear implant; or

1.12 ~~2.6.9~~ Errors of metabolism at risk of major metabolic decompensation; or

1.13 ~~2.6.10~~ Pre and post splenectomy; or

1.14 ~~2.6.11~~ Down syndrome; or

1.15 ~~2.7~~ ~~Are~~ **Is** pregnant; or

1.16 ~~2.8~~ ~~Are children~~ **Is a child** aged four and under who ~~has have~~ been hospitalised for respiratory

illness or ~~has have~~ a history of significant respiratory illness; or

2 ~~3~~ Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital ~~in the 2015 season.~~

Note: The following conditions are excluded from funding:

- ~~asthma not requiring regular preventative therapy; and~~
- ~~hypertension and/or dyslipidaemia without evidence of end-organ disease.~~

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

- 213 MEASLES, MUMPS AND RUBELLA VACCINE (amended restriction)  
 → Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000  
 TCID50 rubella vial with diluent – 1% **DV Jul-14 to 2017**..... 0.00 10 **M-M-R-II**  
 Restricted  
 A maximum of two doses for any patient meeting the following criteria:  
**Initiation – first dose prior to 12 months**  
**Therapy limited to 3 doses**  
**Any of the following:**  
 1 For primary vaccination in children; or  
 2 For revaccination following immunosuppression; or  
 3 For any individual susceptible to measles, mumps or rubella; ~~or~~  
~~4 A maximum of three doses for children who have had their first dose prior to 12 months.~~  
**Initiation – first dose after 12 months**  
**Therapy limited to 2 doses**  
**Any of the following:**  
**1 For primary vaccination in children; or**  
**2 For revaccination following immunosuppression; or**  
**3 For any individual susceptible to measles, mumps or rubella.**  
 Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.
- 214 POLIOMYELITIS VACCINE (amended restriction)  
 → Inj 80 D-antigen units in 0.5 ml syringe  
 – 1% **DV Jul-14 to 2017**..... 0.00 1 **IPOL**  
 Restricted  
 Up to three doses for patients meeting either of the following:  
**Therapy limited to 3 doses**  
**Either:**  
 1 For partially vaccinated or previously unvaccinated individuals; or  
 2 For revaccination following immunosuppression.  
 Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.
- 214 ROTAVIRUS LIVE REASSORTANT ORAL VACCINE (amended restriction)  
 → Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per  
 2 ml, tube – 1% **DV Jul-14 to 2017** ..... 0.00 10 **RotaTeq**  
 Restricted  
 Maximum of three doses for patients meeting the following:  
**Therapy limited to 3 doses**  
**Both:**  
 1 First dose to be administered in infants aged under 15 weeks of age; and  
 2 No vaccination being administered to children aged 8 months or over.
- 214 VARICELLA VACCINE [CHICKEN POX VACCINE] (amended restriction)  
 → Inj 2,000 PFU vial with diluent – 1% **DV Jul-14 to 2017**..... 0.00 1 **Varilrix**  
 Restricted  
 Maximum of two doses for any of the following:  
**Therapy limited to 2 doses**  
**Any of the following:**  
 1 For non-immune patients:  
 1.1 With chronic liver disease who may in future be candidates for transplantation; or  
 1.2 With deteriorating renal function before transplantation; or  
 1.3 Prior to solid organ transplant; or

*continued...*

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 December 2015 (continued)**

*continued...*

- 1.4 Prior to any elective immunosuppression\*.
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist.
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist.
- 4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

\* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days.

# Index

## Pharmaceuticals and brands

<b>A</b>	
Actemra.....	39
Act-HIB.....	13, 42
Adalimumab.....	17, 34
Adefovir dipivoxil.....	22
Advate.....	5
Aerrane.....	15
AFT SLS-free.....	16
Alendronate sodium.....	24, 25
Alendronate sodium with cholecalciferol.....	25
Amoxicillin.....	16
Amoxicillin with clavulanic acid.....	14
Anoro Ellipta.....	12
Aptamil Gold+ Pepti Junior.....	20, 41
Aqueous cream.....	16
Arrow-Gabapentin.....	26
Arrow-Sumatriptan.....	17
Asacol.....	16
Aspirin.....	7
Aubagio.....	15
Augmentin.....	14
Avelox.....	21
Avelox IV 400.....	14, 21
Azacididine.....	29
<b>B</b>	
Bacillus calmette-guerin vaccine.....	42
Balanced Salt Solution.....	19
BCG Vaccine.....	42
Bleomycin sulphate.....	17
Bortezomib.....	30
Breo Ellipta.....	12
Budesonide with eformoterol.....	12
<b>C</b>	
Champix.....	7
Chicken pox vaccine.....	13, 44
Chloramphenicol.....	19
Chlorsig.....	19
Cholecalciferol.....	5
Cipflox.....	16
Ciprofloxacin.....	16
Coal tar with triethanolamine lauryl sulphate and fluorescein.....	6
Concerta.....	28
<b>D</b>	
DBL Bleomycin Sulfate.....	17
Demeclocycline hydrochloride.....	21
Desferal.....	41
Desferrioxamine mesilate.....	41
Desflurane.....	15, 26
Dexamethasone-hameln.....	14
Dexamethasone phosphate.....	14
Dexamfetamine sulfate.....	28
Diatrizoate sodium.....	14
Dimethyl fumarate.....	15
Dornase alfa.....	41
Doxorubicin Ebewe.....	8, 29
Doxorubicin hydrochloride.....	8, 29
<b>E</b>	
Enbrel.....	33
Erlotinib.....	8, 31
Etanercept.....	33
Etoposide.....	15
Everet.....	15
Extensively hydrolysed formula.....	20, 41
Ezemibe.....	16
Ezetimibe.....	16
<b>F</b>	
Filgrastim.....	6
Firazyr.....	19
Fluarix.....	43
Fluticasone furoate with vilanterol.....	12
Fluticasone with salmeterol.....	12
Forteo.....	25
Fosamax.....	24, 25
Fosamax Plus.....	25
<b>G</b>	
Gabapentin.....	26
Gardasil.....	42
Gefitinib.....	9, 32
Glivec.....	32
Glycerin with sodium saccharin.....	19
Glycerin with sucrose.....	19
Glycopyrronium.....	9
Glycopyrronium bromide.....	14
Glycopyrronium with indacaterol.....	11
Gold Pepti Junior Karicare Aptamil.....	41
<b>H</b>	
Haemophilus influenzae type B vaccine.....	13, 42
Hepsera.....	22
HPV.....	42
Human papillomavirus (6, 11, 16 and 18) vaccine.....	42
Humira.....	17, 34
HumiraPen.....	17, 34
<b>I</b>	
Icatibant.....	19
Imatinib mesilate.....	32
Incruse Ellipta.....	10
Infliximab.....	17, 35
Influenza vaccine.....	43
Influvac.....	43
loscan.....	14
IPOL.....	44

# Index

## Pharmaceuticals and brands

Iressa .....	9, 32	Oxaliccord.....	17
Isoflurane.....	15	Oxaliplatin .....	17
Isotane 10.....	16	Oxycodone hydrochloride.....	26
Isotane 20.....	16	OxyNorm .....	26
Isotretinoin.....	16	<b>P</b>	
<b>K</b>		Pegasys.....	23
Ketamine .....	7	Pegasys RBV Combination Pack .....	23
Ketamine-Claris.....	7	Pegylated interferon alfa-2a.....	23
Kogenate FS.....	6	Peptide-based oral feed.....	41
<b>L</b>		Pinetarsol.....	6
Levetiracetam .....	15	Pine tar with trolamine laurilsulfate and fluorescein..	6
Long-acting muscarinic antagonists with long-acting beta-adrenoceptor agonists .....	11	Pizotifen.....	27
<b>M</b>		Pneumococcal (PPV23) polysaccharide vaccine...	13
Mabthera .....	37	Pneumovax 23 .....	13
Measles, mumps and rubella vaccine .....	44	Poliomyelitis vaccine.....	44
Meloxicam .....	26	Pulmozyme.....	41
Mesalazine.....	16	<b>R</b>	
Methylcellulose .....	19	Recombinant factor IX.....	5
Methylcellulose with glycerin and sodium saccharin.....	20	Recombinant factor VIII .....	5, 6
Methylcellulose with glycerin and sucrose .....	20	Remicade .....	17, 35
Methylphenidate hydrochloride .....	28	Rifadin .....	16
Metoprolol - AFT CR.....	6	Rifampicin .....	16
Metoprolol succinate.....	6	Ritalin .....	28
Mixed salt solution for eye irrigation.....	19	Ritalin LA .....	28
M-M-R-II.....	44	Ritalin SR.....	28
m-Nystatin.....	21	Rituximab .....	37
Modafinil.....	28	Rivaroxaban.....	21
Montelukast .....	40	RIXUBIS .....	5
Morococog alfa.....	5	Rizamelt.....	15
Moxifloxacin.....	14, 21	Rizatriptan.....	15
<b>N</b>		RotaTeq.....	44
Neostigmine metilsulfate with glycopyrronium bromide .....	15	Rotavirus live reassortant oral vaccine.....	44
Neurontin .....	26	Rubifen .....	28
Nilstat .....	21	Rubifen SR .....	28
Nonacog gamma.....	5	<b>S</b>	
Nupentin .....	26	Salmeterol .....	12
Nystatin .....	21	Sandomigran .....	27
<b>O</b>		Seebri Breezhaler .....	9
Octocog alfa (Advate).....	5	Seretide .....	12
Octocog alfa (Kogenate FS).....	6	Seretide Accuhaler .....	12
Ora-Blend .....	20	Serevent .....	12
Ora-Blend SF.....	20	Serevent Accuhaler .....	12
Ora-Plus .....	19	Sevoflurane.....	15
Ora-Sweet.....	19	Singulair .....	40
Ora-Sweet SF.....	19	Sodium chloride.....	40
Oratane.....	16	Spacer device .....	14
Orphenadrine hydrochloride.....	7	Spiolto Respimat.....	11
Ospamox .....	16	Spiriva .....	10
		Spiriva Respimat.....	10
		Sumatriptan .....	17
		Sunitinib .....	32

# Index

## Pharmaceuticals and brands

Suprane.....	15, 26	<b>V</b>	
Sutent.....	32	Vaclovir.....	7, 16
Synacthen.....	14	Valaciclovir.....	7, 16, 22
<b>T</b>		Valtrex.....	22
Tarceva.....	8, 31	Varenicline.....	7
Tecfidera.....	15	Varicella vaccine.....	13, 44
Temaccord.....	30	Varilrix.....	13, 44
Temozolomide.....	30	Velcade.....	30
Teriflunomide.....	15	Vidaza.....	29
Teriparatide.....	25	Vigabatrin.....	27
Tetracosactide.....	14	Vital.....	41
Tetracosactrin.....	14	Vital HN.....	41
Thalidomide.....	31	Vit.D3.....	5
Thalomid.....	31	Volumatic.....	14
Tiotropium bromide.....	10	<b>X</b>	
Tiotropium bromide with olodaterol.....	11	Xarelto.....	21
Tocilizumab.....	39	Xyntha.....	5
<b>U</b>		<b>Z</b>	
Ultibro Breezhaler.....	11	Zarzio.....	6
Umeclidinium.....	10	Ziprasidone.....	17
Umeclidinium with vilanterol.....	12	Zusdone.....	17



New Zealand  
Permit No. 478



**Hospital Medicines List queries:**

**Fax: 64 4 974 7819**

**Email: [HML@pharmac.govt.nz](mailto:HML@pharmac.govt.nz)**

**[www.pharmac.health.nz/medicines/hospital-pharmaceuticals](http://www.pharmac.health.nz/medicines/hospital-pharmaceuticals)**

Pharmaceutical Management Agency  
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand  
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

**New Zealand** Government

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand